Superior Vena Cava Syndrome
- Author: Todd A Nickloes, DO, FACOS; Chief Editor: Vincent Lopez Rowe, MD more...
Superior vena cava syndrome (SVCS) is obstruction of blood flow through the superior vena cava (SVC). It is a medical emergency and most often manifests in patients with a malignant disease process within the thorax. A patient with SVCS requires immediate diagnostic evaluation and therapy.
William Hunter first described the syndrome in 1757 in a patient with syphilitic aortic aneurysm. In 1954, Schechter reviewed 274 well-documented cases of SVCS reported in the literature; 40% of them were due to syphilitic aneurysms or tuberculous mediastinitis.
Since the early reports, these infections have gradually decreased as the primary cause of SVC obstruction. Lung cancer, particularly adenocarcinoma, is now the underlying process in approximately 70% of patients with SVCS.[3, 4, 5] However, as many as 40% of cases are attributable to nonmalignant causes.
The SVC is the major drainage vessel for venous blood from the head, neck, upper extremities, and upper thorax. It is located in the middle mediastinum and is surrounded by relatively rigid structures such as the sternum, trachea, right bronchus, aorta, pulmonary artery, and the perihilar and paratracheal lymph nodes. It extends from the junction of the right and left innominate veins to the right atrium, a distance of 6-8 cm. It is a thin-walled, low-pressure, vascular structure. This wall is easily compressed as it traverses the right side of the mediastinum.
Obstruction of the SVC may be caused by neoplastic invasion of the venous wall associated with intravascular thrombosis or, more simply, by extrinsic pressure of a tumor mass against the relatively thin-walled SVC. Complete SVC obstruction is the result of intravascular thrombosis in combination with extrinsic pressure. Incomplete SVC obstruction is more often secondary to extrinsic pressure without thrombosis. Other causes include compression by intravascular arterial devices. The incidence is on the rise, in line with the increased use of endovascular devices.
An obstructed SVC initiates collateral venous return to the heart from the upper half of the body through four principal pathways. The first and most important pathway is the azygous venous system, which includes the azygos vein, the hemiazygos vein, and the connecting intercostal veins. The second pathway is the internal mammary venous system plus tributaries and secondary communications to the superior and inferior epigastric veins. The long thoracic venous system, with its connections to the femoral veins and vertebral veins, provides the third and fourth collateral routes, respectively.
Despite these collateral pathways, venous pressure is almost always elevated in the upper compartment if obstruction of the SVC is present. Venous pressure as high as 200-500 cm H2 O has been recorded in patients with severe SVCS.
More than 80% of cases of SVCS are caused by malignant mediastinal tumors.[8, 9, 10] Bronchogenic carcinomas account for 75-80% of all these cases, with most of these being small-cell carcinomas. Non-Hodgkin lymphoma (especially the large-cell type) account for 10-15%. Causes of SVCS appear similar to the relative incidence of primary lung and mediastinal tumors. Rare malignant diagnoses include Hodgkin disease, metastatic cancers, primary leiomyosarcomas of the mediastinal vessels, and plasmocytomas.[12, 13, 14]
Nonmalignant conditions that can cause SVCS include the following:
Benign mediastinal tumors such as teratoma, cystic hygroma, thymoma, and dermoid cyst
Cardiac causes, such as pericarditis and atrial myxoma
Thrombosis related to the presence of central vein catheters
These account for approximately 22% of cases of SVCS.[12, 15, 16, 17]
United States statistics
SVCS develops in 5-10% of patients with a right-side malignant intrathoracic mass lesion. In 1969, Salsali and Cliffton observed SVCS in 4.2% of 4960 patients with lung cancer; 80% of the tumors inducing SVCS were of the right lung. In five large series of small-cell lung cancer, 9-19% of patients demonstrated SVCS. In 1987, Armstrong and Perez found SVCS in 1.9% of 952 patients with lymphoma.
Age-, sex-, and race-related demographics
Malignant causes of SVCS are predominantly observed in individuals aged 40-60 years. Benign causes account for most of the cases diagnosed in individuals aged 30-40 years. Obstruction of the SVC in the pediatric age group is rare and has a different etiologic spectrum.
Malignant causes of SVCS are most commonly observed in males because of the high incidence of lung cancer in this population. In contrast, cases related to benign causes show no sex-related differences in frequency.
The frequency of SVCS in different races depends largely on the frequency of lung cancer and lymphomas in these populations.
Survival in patients with SVCS depends mainly on the course of the underlying disease. No mortality, per se, results directly from mild venous congestion.
In patients with benign SVCS, life expectancy is unchanged. If SVCS is secondary to a malignant process, patient survival correlates with tumor histology. Patients with signs and symptoms of laryngeal and cerebral edema have the most life-threatening manifestations of SVCS and are in danger of sudden death.
Clinical observations show that approximately 10% of patients with a bronchogenic carcinoma and 45% of patients with lymphoma treated with irradiation live at least 30 months. In contrast, patients with untreated malignant SVCS survive for only about 30 days. Survival for those who do not respond to treatment is similar.
National Cancer Institute. Cardiopulmonary syndromes. 2005. [Full Text].
Schechter MM. The superior vena cava syndrome. Am J Med Sci. 1954 Jan. 227(1):46-56. [Medline].
Flounders J. Superor vena cava syndrome. Oncol Nurs Forum. 2003. 30(4):E84-8.
Ahmann FR. A reassessment of the clinical implications of the superior vena caval syndrome. J Clin Oncol. 1984 Aug. 2(8):961-9. [Medline].
Hassikou H, Bono W, Bahiri R, et al. Vascular involvement in Behçet's disease. Two case reports. Joint Bone Spine. 2002 Jun. 69(4):416-8. [Medline].
Hunter W. The history of an aneurysm of the aorta with some remarks on aneurysms in general. Med Obs Enq. 1757. 1:323-357.
Armstrong BA, Perez CA, Simpson JR, et al. Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys. 1987 Apr. 13(4):531-9. [Medline].
Escalante CP. Causes and management of superior vena cava syndrome. Oncology (Williston Park). 1993 Jun. 7(6):61-8; discussion 71-2, 75-7. [Medline].
Schraufnagel DE, Hill R, Leech JA, et al. Superior vena caval obstruction. Is it a medical emergency?. Am J Med. 1981 Jun. 70(6):1169-74. [Medline].
Klassen KP, Andrews NC, Curtis GM. Diagnosis and treatment of superior-vena-cava obstruction. AMA Arch Surg. 1951 Sep. 63(3):311-25. [Medline].
Sakura M, Tsujii T, Yamauchi A, et al. Superior vena cava syndrome caused by supraclavicular lymph node metastasis of renal cell carcinoma. Int J Clin Oncol. 2007 Oct. 12(5):382-4. [Medline].
Nieto AF, Doty DB. Superior vena cava obstruction: clinical syndrome, etiology, and treatment. Curr Probl Cancer. 1986 Sep. 10(9):441-84. [Medline].
Lochridge SK, Knibbe WP, Doty DB. Obstruction of the superior vena cava. Surgery. 1979 Jan. 85(1):14-24. [Medline].
Bigsby R, Greengrass R, Unruh H. Diagnostic algorithm for acute superior vena caval obstruction (SVCO). J Cardiovasc Surg (Torino). 1993 Aug. 34(4):347-50. [Medline].
Parish JM, Marschke RF Jr, Dines DE, et al. Etiologic considerations in superior vena cava syndrome. Mayo Clin Proc. 1981 Jul. 56(7):407-13. [Medline].
Marcy PY, Magne N, Bentolila F, et al. Superior vena cava obstruction: is stenting necessary?. Support Care Cancer. 2001 Mar. 9(2):103-7. [Medline].
Akoglu H, Yilmaz R, Peynircioglu B, et al. A rare complication of hemodialysis catheters: superior vena cava syndrome. Hemodial Int. 2007 Oct. 11(4):385-91. [Medline].
Houman M, Ksontini I, Ben Ghorbel I, et al. Association of right heart thrombosis, endomyocardial fibrosis, and pulmonary artery aneurysm in Behçet's disease. Eur J Intern Med. 2002 Oct. 13(7):455. [Medline].
Salsali M, Cliffton EE. Superior vena caval obstruction in carcinoma of lung. N Y State J Med. 1969 Nov 15. 69(22):2875-80. [Medline].
Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006 Jan. 85(1):37-42. [Medline].
Blalock A, Cunningham RS, Robinson CS. Experimental production of chylothorax by occlusion of the superior vena cava. Ann Surg. 1936 Sep. 104(3):359-64. [Medline].
Scarantino C, Salazar OM, Rubin P, et al. The optimum radiation schedule in treatment of superior vena caval obstruction: importance of 99mTc scintiangiograms. Int J Radiat Oncol Biol Phys. 1979 Nov-Dec. 5(11-12):1987-95. [Medline].
Abner A. Approach to the patient who presents with superior vena cava obstruction. Chest. 1993 Apr. 103(4 Suppl):394S-397S. [Medline].
Dosios T, Theakos N, Chatziantoniou C. Cervical mediastinoscopy and anterior mediastinotomy in superior vena cava obstruction. Chest. 2005 Sep. 128(3):1551-6. [Medline].
Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002 Oct. 14(5):338-51. [Medline].
Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. Arch Intern Med. 1993 Feb 8. 153(3):384-7. [Medline].
Maddox AM, Valdivieso M, Lukeman J, et al. Superior vena cava obstruction in small cell bronchogenic carcinoma. Clinical parameters and survival. Cancer. 1983 Dec 1. 52(11):2165-72. [Medline].
Perez-Soler R, McLaughlin P, Velasquez WS, et al. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. J Clin Oncol. 1984 Apr. 2(4):260-6. [Medline].
Adelstein DJ, Hines JD, Carter SG, et al. Thromboembolic events in patients with malignant superior vena cava syndrome and the role of anticoagulation. Cancer. 1988 Nov 15. 62(10):2258-62. [Medline].
Watkinson AF, Yeow TN, Fraser C. Endovascular stenting to treat obstruction of the superior vena cava. BMJ. 2008 Jun 21. 336(7658):1434-7. [Medline].
Garcia Monaco R, Bertoni H, Pallota G, et al. Use of self-expanding vascular endoprostheses in superior vena cava syndrome. Eur J Cardiothorac Surg. 2003 Aug. 24(2):208-11. [Medline].
Smayra T, Otal P, Chabbert V, et al. Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Intervent Radiol. 2001 Nov-Dec. 24(6):388-94. [Medline].
Thony F, Moro D, Witmeyer P, et al. Endovascular treatment of superior vena cava obstruction in patients with malignancies. Eur Radiol. 1999. 9(5):965-71. [Medline].
Yim CD, Sane SS, Bjarnason H. Superior vena cava stenting. Radiol Clin North Am. 2000 Mar. 38(2):409-24. [Medline].
Rizvi AZ, Kalra M, Bjarnason H, Bower TC, Schleck C, Gloviczki P. Benign superior vena cava syndrome: stenting is now the first line of treatment. J Vasc Surg. 2008 Feb. 47(2):372-80. [Medline].
del Río Solá ML, Fuente Garrido R, Gutiérrez Alonso V, Vaquero Puerta C. Endovascular treatment of superior vena cava syndrome caused by malignant disease. J Vasc Surg. 2014 Jun. 59(6):1705-6. [Medline].
Garlitski AC, Swingle JD, Aizer A, et al. Percutaneous treatment of the superior vena cava syndrome via an excimer laser sheath in a patient with a single chamber atrial pacemaker. J Interv Card Electrophysiol. 2006 Sep. 16(3):203-6. [Medline].
Nunnelee JD. Superior vena cava syndrome. J Vasc Nurs. 2007 Mar. 25(1):2-5; quiz 6. [Medline].
Rice TW. Pleural effusions in superior vena cava syndrome: prevalence, characteristics, and proposed pathophysiology. Curr Opin Pulm Med. 2007 Jul. 13(4):324-7. [Medline].
Vogelzang R, Schindler N. Superor vena cava syndrome: endovascular therapy. Gloviczki P, Yoa J, eds. Handbook of venous disorders. (2nd ed). London: Arnold; 2001. 401-7.